GlassScriptPhysician profile
Malarie M Jackson
NPI 1285056887
$3,786.39
in general payments reported to CMS, 2019-2025
41 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $806 · 2022: $872 · 2023: $813 · 2024: $796 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,100 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.39 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $745.34 | 2021-2025 | |
| Amgen INC. | $268.08 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $265.86 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $254.09 | 2021-2025 | |
| Novo Nordisk INC | $240.56 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $211.36 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $157.85 | 2023-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $130.98 | 2021-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $119.43 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $115.26 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $103.83 | 2024 | Qelbree |
| Corium, LLC | $101.58 | 2022-2023 | Azstarys |
| Organon LLC | $100.15 | 2023-2025 | Nexplanon |
| Biohaven Pharmaceuticals, INC. | $78.68 | 2021 | |
| Glaxosmithkline, LLC. | $78.31 | 2022-2023 | Shingrix, Trelegy Ellipta |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malarie Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.